跳至主要内容
临床试验/NCT05007028
NCT05007028已完成不适用

Nitrous Oxide for Late-Life Depression : a Randomized Controlled Trial With Comparator - PROTO-BRAIN

University Hospital, Tours1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2021年11月16日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
1
主要终点
Change in MADRS

研究概览

简要总结

Resistant Depression is a common condition in older adults and there is an urgent need for novel antidepressant in this population. Nitrous Oxide (N2O) has recently shown rapid antidepressant effect in midlife depression but no study has currently investigated the efficacy and safety of N2O in Late-Life Depression (LLD), while N2O may prove to be an ideal treatment for LLD because of glutamatergic antagonism and cerebrovascular effects and also a relatively good safety profile.

The goal of our study is to compare changes in depressive symptoms after 2 hours, 24 hours, 1 week and 2 week of a 1-hour exposure to EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide) versus Medical Air.

Secondary Objectives include comparing differences in neuroimaging measures between 3 groups (responders and non-responders in the EMONO group, and patients in the control group).

详细描述

Secondary objectives include:

  • To compare changes in Brain Tissue Pulsatility (BTP) as measured with Ultrasound Tissue Pulsatility Imaging (TPI) between responders in the EMONO group (MADRS change of at least 50%), non-responders in the EMONO group (MADRS change of no more than 50%) and in the Air Medical group
  • To compare baseline differences in structural (brain volumes, white matter hyperintensities) and functional (resting state connectivity in BOLD, Brain Pulsatility in BOLD, Brain Perfusion in ASL) among the 3 groups
  • To compare changes in depressive and anxiety symptoms between the active and control group, as assess with Hamilton scale, CGI scale, QIDS-SR, VAS and the STAI scale
  • To compare safety between the active and control group, as assessed with SSI, YMRS, CADSS, BPRS

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
60 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 60-90 years-old
  • Major Depressive Episode according to DSM-5 criteria, confirmed by the MINI - Mini International Neuropsychiatric Interview
  • MADRS score greater than 20 (Montgomery Asberg Depression Rating Scale)
  • Patient resistant to at least one well-conducted antidepressant treatment, as documented by the MGH-ATRQ scale
  • Patient who can undergo N2O diffusion via a facial mask
  • Patient who has signed an informed consent
  • Person affiliated with a social security scheme

排除标准

  • Bipolar disorder, schizophrenic disorder, neurodegenerative disease, documented by the MINI and the MMSE (non-inclusion if MMSE < 24/30), addictive disorder
  • Unstable somatic pathology (including unstable neurological or cardiological diseases at risk of interfering with N2O diffusion)
  • Presence of active and significant psychotic symptoms, at investigator's discretion
  • Contraindications to EMONO (50%N2O/ 50%O2) : pneumothorax, emphysema, bowel obstruction, intracranial hypertension, chronic deficiency in vitamin B12 or B9
  • Contraindications to MRI, including claustrophobia
  • Legal incapacity and/or other circumstances unabling the patient to understand the nature, purpose or consequences of the study
  • A person participating in a drug clinical trial or during a period of exclusion from any clinical study

研究组 & 干预措施

Nitrous Oxide

Experimental

Active Drug: EMONO (Equimolar Mixture of Oxygen and Nitrous Oxide)

干预措施: EMONO (Drug)

Medical air

Placebo Comparator

Control Drug: Medical air : 78% N2 / 22% O2

干预措施: Medical Air (Drug)

结局指标

主要结局

Change in MADRS

时间窗: Baseline, 2 hours, 24 hours, 1 week, 2 weeks

montgomery asberg depression scale for symptoms severity

次要结局

  • MRI(At Baseline)
  • Change in QIDS-SR(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in YMRS(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in STAI(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in Clinician Administered Dissociative States Scale(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in Brain Tissue Pulsatility(Baseline and immediately after the intervention)
  • Change in HDRS 17 items(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in CGI(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in VAS(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in SSI(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)
  • Change in BPRS(Baseline, 2 hours, 24 hours, 1 week, 2 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Nitrous Oxide for Late-Life Depression - PROTO-BRAIN | 临床试验